IL160230A0 - Use of il-18 inhibitors - Google Patents

Use of il-18 inhibitors

Info

Publication number
IL160230A0
IL160230A0 IL16023002A IL16023002A IL160230A0 IL 160230 A0 IL160230 A0 IL 160230A0 IL 16023002 A IL16023002 A IL 16023002A IL 16023002 A IL16023002 A IL 16023002A IL 160230 A0 IL160230 A0 IL 160230A0
Authority
IL
Israel
Prior art keywords
inhibitors
Prior art date
Application number
IL16023002A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL160230A0 publication Critical patent/IL160230A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL16023002A 2001-08-10 2002-08-01 Use of il-18 inhibitors IL160230A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118811 2001-08-10
EP02100735 2002-06-20
PCT/EP2002/008591 WO2003013577A2 (en) 2001-08-10 2002-08-01 Use of il-18 inhibitors in hypersensitivity disorders

Publications (1)

Publication Number Publication Date
IL160230A0 true IL160230A0 (en) 2004-07-25

Family

ID=26076673

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16023002A IL160230A0 (en) 2001-08-10 2002-08-01 Use of il-18 inhibitors
IL160230A IL160230A (en) 2001-08-10 2004-02-05 Il-18 inhibitors for the preparation of hypersensitivity drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160230A IL160230A (en) 2001-08-10 2004-02-05 Il-18 inhibitors for the preparation of hypersensitivity drugs

Country Status (26)

Country Link
US (1) US20040247598A1 (pl)
EP (1) EP1423138B1 (pl)
JP (1) JP4301942B2 (pl)
KR (1) KR20040030948A (pl)
CN (1) CN100500210C (pl)
AR (1) AR035274A1 (pl)
AU (1) AU2002331376B2 (pl)
BR (1) BRPI0211827B8 (pl)
CA (1) CA2456247C (pl)
CY (1) CY1116137T1 (pl)
DK (1) DK1423138T3 (pl)
EA (1) EA006745B1 (pl)
ES (1) ES2533253T3 (pl)
HR (1) HRP20040071B1 (pl)
HU (1) HU230377B1 (pl)
IL (2) IL160230A0 (pl)
ME (1) ME00547B (pl)
MX (1) MXPA04001230A (pl)
NO (1) NO335688B1 (pl)
PL (1) PL227130B1 (pl)
PT (1) PT1423138E (pl)
RS (1) RS52224B (pl)
SI (1) SI1423138T1 (pl)
UA (1) UA78516C2 (pl)
WO (1) WO2003013577A2 (pl)
ZA (1) ZA200400442B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552908A (en) * 2004-06-30 2009-11-27 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
JP5937015B2 (ja) * 2010-12-16 2016-06-22 株式会社明治 遅延型過敏症軽減剤
WO2024261470A1 (en) * 2023-06-20 2024-12-26 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
EP1062210B1 (en) * 1998-03-09 2005-06-01 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
WO2000071719A1 (en) * 1999-05-20 2000-11-30 Hyseq, Inc. Interleukin-1 hy2 materials and methods
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
NO335688B1 (no) 2015-01-19
HK1069780A1 (zh) 2005-06-03
NO20040370L (no) 2004-03-23
HRP20040071A2 (en) 2004-10-31
RS52224B (sr) 2012-10-31
EA006745B1 (ru) 2006-04-28
CA2456247C (en) 2013-09-10
CY1116137T1 (el) 2017-02-08
BRPI0211827B8 (pt) 2021-05-25
HU230377B1 (hu) 2016-03-29
HUP0401323A3 (en) 2006-01-30
KR20040030948A (ko) 2004-04-09
UA78516C2 (en) 2007-04-10
HRP20040071B1 (hr) 2015-08-28
PL368231A1 (pl) 2005-03-21
EP1423138B1 (en) 2014-12-24
JP2005501080A (ja) 2005-01-13
CN1568193A (zh) 2005-01-19
BR0211827A (pt) 2004-08-31
US20040247598A1 (en) 2004-12-09
WO2003013577A3 (en) 2003-09-25
IL160230A (en) 2014-11-30
AU2002331376B2 (en) 2007-06-14
ME00547B (me) 2011-12-20
BRPI0211827B1 (pt) 2019-07-23
CA2456247A1 (en) 2003-02-20
EA200400296A1 (ru) 2004-06-24
WO2003013577A2 (en) 2003-02-20
DK1423138T3 (en) 2015-02-23
PL227130B1 (pl) 2017-10-31
CN100500210C (zh) 2009-06-17
ES2533253T3 (es) 2015-04-08
JP4301942B2 (ja) 2009-07-22
MXPA04001230A (es) 2004-05-27
SI1423138T1 (sl) 2015-04-30
YU11904A (sh) 2006-08-17
AR035274A1 (es) 2004-05-05
EP1423138A2 (en) 2004-06-02
PT1423138E (pt) 2015-02-09
ZA200400442B (en) 2005-03-30
HUP0401323A2 (hu) 2004-10-28

Similar Documents

Publication Publication Date Title
HUP0300061A3 (en) Use of il-18 inhibitors
GB0025782D0 (en) Use of inhibitors
EP1549316A4 (en) HAMMER OF TFGbeta
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PT1438306E (pt) Derivados de uk-20
IL157657A0 (en) Metalloproteinase inhibitors
IL157570A0 (en) Metalloproteinase inhibitors
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL149106A0 (en) Therapeutic use of selective pde10 inhibitors
AU2002357882A8 (en) Small-molecule inhibitors of interleukin-2
IL157650A0 (en) Metalloproteinase inhibitors
AU2003217105A8 (en) Novel of cytokine inhibitors
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
IL131047A0 (en) Use of il-18 inhibitors
PL368321A1 (pl) Zastosowanie cystationiny
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
IL160230A0 (en) Use of il-18 inhibitors
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2002305868A1 (en) Inhibitors of reggamma
ZA200205471B (en) Use of IL-18 inhibitors.
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
IL147675A0 (en) Use of il-18 inhibitors